PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a turnover of €15.2 million for the second quarter of 2010 versus €1.5 million in Q2 2009.
